Last reviewed · How we verify
NCT02661776
The Change of NK Cell Activity After Head and Neck Cancer Surgery
trial in The Patients Undergoing Head and Neck Surgery Including Tumor Removal and Reconstruction With Flap in 29 participants. Completed in 4 May 2017.
4 May 2017
Quick facts
| Lead sponsor | Yonsei University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 29 |
| Start date | 24 March 2016 |
| Primary completion | 4 May 2017 |
| Estimated completion | 4 May 2017 |
| Sites | 1 location across South Korea |
Conditions studied
- The Patients Undergoing Head and Neck Surgery Including Tumor Removal and Reconstruction With Flap — all drugs for The Patients Undergoing Head and Neck Surgery Including Tumor Removal and Reconstruction With Flap →
Sponsor
Yonsei University
Who can join
19 and older, any sex, with The Patients Undergoing Head and Neck Surgery Including Tumor Removal and Reconstruction With Flap. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cellular immunity can be changed after surgery and anesthesia. Tissue injury by surgical procedures significantly reduces the immune function in proportion to the degree of tissue injury. In addition, the use of opioids as analgesics during the perioperative period depress cellular immunity, in particular the activity of the natural killer (NK) cells. This perioperative immunosuppression may cause deleterious consequences on postoperative outcome in cancer patients. The aim of this study is to confirm the presence or extent of the change of NK cell activity between before and after head and neck surgery. Additionally, investigators will identify the clinical or genetic factors related to the change of NK cell activity.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Dysfunctional Natural Killer Cells in the Aftermath of Cancer Surgery.
Angka L, Khan ST, Kilgour MK, Xu R, et al · · 2017 · cited 53× · PMID 28817109 · DOI 10.3390/ijms18081787
Verify or expand the search:
- PubMed search for NCT02661776
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Yonsei University trials
Trials by the same sponsor.
- NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
- NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
- NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
- NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
- NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02661776 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yonsei University
- Last refreshed: 2 October 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02661776.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing